Expression of PD-L1 Is Associated with Inflammatory Microenvironment in Surgical Specimens of Non-Small Cell Lung Cancer
Abstract
:1. Introduction
2. Materials and Methods
3. Results
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Barta, J.A.; Powell, C.A.; Wisnivesky, J.P. Global Epidemiology of Lung Cancer. Ann. Glob. Health 2019, 85, 8. [Google Scholar] [CrossRef] [Green Version]
- Berghoff, A.S.; Bellosillo, B.; Caux, C.; de Langen, A.; Mazieres, J.; Normanno, N.; Preusser, M.; Provencio, M.; Rojo, F.; Wolf, J.; et al. Immune checkpoint inhibitor treatment in patients with oncogene-addicted non-small cell lung cancer (NSCLC): Summary of a multidisciplinary round-table discussion. ESMO Open 2019, 4, e000498. [Google Scholar] [CrossRef] [Green Version]
- Han, Y.; Liu, D.; Li, L. PD-1/PD-L1 pathway: Current researches in cancer. Am. J. Cancer Res. 2020, 10, 727–742. [Google Scholar] [PubMed]
- Mallett, G.; Laurence, A.; Amarnath, S. Programmed Cell Death-1 Receptor (PD-1)-Mediated Regulation of Innate Lymphoid Cells. Int. J. Mol. Sci. 2019, 20, 2836. [Google Scholar] [CrossRef] [Green Version]
- Petrova, V.; Arkhypov, I.; Weber, R.; Groth, C.; Altevogt, P.; Utikal, J.; Umansky, V. Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma. Int. J. Mol. Sci. 2020, 21, 2367. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- de Jong, F.C.; Rutten, V.C.; Zuiverloon, T.C.M.; Theodorescu, D. Improving Anti-PD-1/PD-L1 Therapy for Localized Bladder Cancer. Int. J. Mol. Sci. 2021, 22, 2800. [Google Scholar] [CrossRef] [PubMed]
- Sui, H.; Ma, N.; Wang, Y.; Li, H.; Liu, X.; Su, Y.; Yang, J. Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies. J. Immunol. Res. 2018, 2018, 6984948. [Google Scholar] [CrossRef] [Green Version]
- Ohaegbulam, K.C.; Assal, A.; Lazar-Molnar, E.; Yao, Y.; Zang, X. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol. Med. 2015, 21, 24–33. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Naito, T.; Udagawa, H.; Sato, J.; Horinouchi, H.; Murakami, S.; Goto, Y.; Kanda, S.; Fujiwara, Y.; Yamamoto, N.; Zenke, Y.; et al. A Minimum Of 100 Tumor Cells in a Single Biopsy Sample Is Required to Assess Programmed Cell Death Ligand 1 Expression in Predicting Patient Response to Nivolumab Treatment in Nonsquamous Non-Small Cell Lung Carcinoma. J. Thorac. Oncol. 2019, 14, 1818–1827. [Google Scholar] [CrossRef]
- Lin, G.; Fan, X.; Zhu, W.; Huang, C.; Zhuang, W.; Xu, H.; Lin, X.; Hu, D.; Huang, Y.; Jiang, K.; et al. Prognostic significance of PD-L1 expression and tumor infiltrating lymphocyte in surgically resectable non-small cell lung cancer. Oncotarget 2017, 8, 83986–83994. [Google Scholar] [CrossRef]
- Mirsadraee, S.; Oswal, D.; Alizadeh, Y.; Caulo, A.; van Beek, E.J. The 7th lung cancer TNM classification and staging system: Review of the changes and implications. World J. Radiol. 2012, 4, 128–134. [Google Scholar] [CrossRef]
- Miyazawa, T.; Marushima, H.; Saji, H.; Kojima, K.; Hoshikawa, M.; Takagi, M.; Nakamura, H. PD-L1 Expression in Non-Small-Cell Lung Cancer Including Various Adenocarcinoma Subtypes. Ann. Thorac. Cardiovasc. Surg. 2019, 25, 1–9. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ikeda, S.; Okamoto, T.; Okano, S.; Umemoto, Y.; Tagawa, T.; Morodomi, Y.; Kohno, M.; Shimamatsu, S.; Kitahara, H.; Suzuki, Y.; et al. PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non-Small Cell Lung Cancer. J. Thorac. Oncol. 2016, 11, 62–71. [Google Scholar] [CrossRef] [PubMed]
- Inoue, Y.; Yoshimura, K.; Mori, K.; Kurabe, N.; Kahyo, T.; Mori, H.; Kawase, A.; Tanahashi, M.; Ogawa, H.; Inui, N.; et al. Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer. Oncotarget 2016, 7, 32113–32128. [Google Scholar] [CrossRef]
- Muller, S.; Chen, Y.; Ginter, T.; Schafer, C.; Buchwald, M.; Schmitz, L.M.; Klitzsch, J.; Schutz, A.; Haitel, A.; Schmid, K.; et al. SIAH2 antagonizes TYK2-STAT3 signaling in lung carcinoma cells. Oncotarget 2014, 5, 3184–3196. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tancos, V.; Grendar, M.; Farkasova, A.; Hutka, Z.; Kviatkovska, Z.; Plank, L. Programmed Death-Ligand 1 Expression in Non-Small Cell Lung Carcinoma Biopsies and Its Association with Tumor Infi ltrat ing Lymphocytes and the Degree of Desmoplasia. Klin. Onkol. 2020, 33, 55–65. [Google Scholar] [CrossRef] [Green Version]
- Pawelczyk, K.; Piotrowska, A.; Ciesielska, U.; Jablonska, K.; Gletzel-Plucinska, N.; Grzegrzolka, J.; Podhorska-Okolow, M.; Dziegiel, P.; Nowinska, K. Role of PD-L1 Expression in Non-Small Cell Lung Cancer and Their Prognostic Significance according to Clinicopathological Factors and Diagnostic Markers. Int. J. Mol. Sci. 2019, 20, 824. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jiang, T.; Shi, J.; Dong, Z.; Hou, L.; Zhao, C.; Li, X.; Mao, B.; Zhu, W.; Guo, X.; Zhang, H.; et al. Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma. J. Hematol. Oncol. 2019, 12, 75. [Google Scholar] [CrossRef] [Green Version]
- Brambilla, E.; Le Teuff, G.; Marguet, S.; Lantuejoul, S.; Dunant, A.; Graziano, S.; Pirker, R.; Douillard, J.Y.; Le Chevalier, T.; Filipits, M.; et al. Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer. J. Clin. Oncol. 2016, 34, 1223–1230. [Google Scholar] [CrossRef]
- Zhang, Y.; Li, J.; Wang, R.; Li, Y.; Pan, Y.; Cai, D.; Hu, H.; Li, H.; Ye, T.; Luo, X.; et al. The prognostic and predictive value of solid subtype in invasive lung adenocarcinoma. Sci. Rep. 2014, 4, 7163. [Google Scholar] [CrossRef] [Green Version]
- Liu, W.; Shao, Y.; Guan, B.; Hao, J.; Cheng, X.; Ji, K.; Wang, K. Extracapsular extension is a powerful prognostic factor in stage IIA-IIIA non-small cell lung cancer patients with completely resection. Int. J. Clin. Exp. Pathol. 2015, 8, 11268–11277. [Google Scholar] [PubMed]
- Herbst, R.S.; Baas, P.; Perez-Gracia, J.L.; Felip, E.; Kim, D.W.; Han, J.Y.; Molina, J.R.; Kim, J.H.; Dubos Arvis, C.; Ahn, M.J.; et al. Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: An updated analysis of KEYNOTE-010 trial. Ann. Oncol. 2019, 30, 281–289. [Google Scholar] [CrossRef] [PubMed]
VARIABLES | PD-L1 Tumour Proportion Score | |||
---|---|---|---|---|
0 | ≥1 | p | ||
Gender; n (%) | ||||
Males | 76 (70) | 43 (70) | 33 (70) | 1 * |
Females | 32 (30) | 18 (30) | 14 (30) | |
Age; median (Q1–Q3; min–max) | 65 (58–71; 45–82) | 66 (61–73; 51–84) | 0.268 * | |
NSCLC; n (%) | ||||
ADC | 68 (63) | 40 (67) | 28 (58) | 0.434 * |
SCC | 35 (32) | 17 (28) | 18 (38) | |
NSCLC-NOS | 5 (5) | 3 (5) | 2 (4) | |
Tumour size; median (Q1–Q3; min–max) | 3 (2–4.5; 1–15) | 3 (2–4; 1–10) | 0.066 ** | |
Gradus; n (%) | ||||
1 | 15 (14.2) | 11 (18.6) | 4 (8.5) | 0.147* |
2 | 59 (55.7) | 34 (57.6) | 25 (53.2) | |
3 | 32 (30.2) | 14 (23.7) | 18 (38.3) | |
Atelectasis or pneumonitis; n (%) | ||||
Yes | 49 (45) | 23 (38) | 38 (62) | 0.104 * |
No | 59 (55) | 26 (55) | 21 (45) | |
Lympho-vascular invasion; n (%) | ||||
No | 47 (44) | 23 (38) | 24 (51) | 0.233 * |
Yes | 61 (56) | 38 (62) | 23 (49) | |
Stage; n (%) | ||||
1 | 51 (47.2) | 27 (44.3) | 24 (51.1) | 0.320 * |
2 | 31 (28.7) | 16 (26.2) | 15 (31.9) | |
3 | 26 (24.1) | 18 (29.5) | 8 (17) | |
ADC subtype; n (%) | ||||
Acinar | 37 (56.9) | 20 (52.6) | 17 (63) | 0.050 * |
Papillary | 14 (21.5) | 12 (31.6) | 2 (7.4) | |
Solid | 14 (21.5) | 6 (15.8) | 8 (29.6) | |
ADC subtype; n (%) | ||||
Acinar | 37 (72) | 20 (62) | 17 (89) | 0.053 † |
Papillary | 14 (28) | 12 (38) | 2 (11) | |
ADC subtype; n (%) | ||||
Papillary | 14 (50) | 12 (67) | 2 (20) | 0.046 † |
Solid | 14 (50) | 6 (33) | 8 (80) |
Median Expression Value for PD-L1 (%) (Q1–Q3; Min–Max) | p | ||
---|---|---|---|
Histological type | |||
ADC | 0 (0–20; 0–100) | 0.699 * | |
SCC | 1 (0–25; 0–90) | ||
Lympho-vascular invasion | |||
No | 1 (0–50; 0–100) | 0.95 * | |
Yes | 0 (0–4; 0–100) | ||
Lymph node status | |||
Negative | 0 (0–25; 0–100) | 0.705 * | |
Positive | 0 (0–5; 0–100) | ||
Pathological stage | |||
1 | 0 (0–25; 0–100) | 0.505 ** | |
2 | 0 (0–5; 0–90) | ||
3 | 0 (0–5,7; 0–100) | ||
IMR | |||
Absent | 0 (0–1; 0–90) | 0.039 ** | |
Low | 0 (0–25; 0–100) | ||
Strong | 3 (0–50; 0–100) | ||
Histological grade | |||
1 | 0 (0–1; 0–60) | 0.119 * | |
2 | 0 (0–5; 0–100) | ||
3 | 1 (0–50; 0–100) | ||
ADC subtype | |||
Acinar | 0 (0–12,5; 0–60) | 0.014 ** | |
Papillary | 0 (0–0; 0–20) | ||
Solid | 25.5 (0–90; 0–100) |
Primary Tumour | All | PD-L1 in Lymph Node | p | |
---|---|---|---|---|
Negative (0) | Positive (>0) | |||
Expression of PD-L1; median (Q1–Q3; min–max) | 0 (0–19; 0–100) | 0 (0–60; 0–100) | 0 (0–4.5; 0–90) | 0.673 * |
PD-L1; n (%) | ||||
negative | 22 (58) | 9 (70) | 13 (52) | 1 ** |
positive | 16 (42) | 4 (30) | 12 (48) |
Variable | OS (Months) | SE | 95% CI | Median | LR | p |
---|---|---|---|---|---|---|
Gender | ||||||
Males | 46 | 3.9 | 38–53 | 44 | 1.65 | 0.199 |
Females | 50 | 5 | 41–60 | |||
Histologic type | ||||||
ADC | 49.8 | 3.9 | 42.2–57.5 | 62 | 2.14 | 0.143 |
SCC | 42.4 | 5.6 | 31.4–53.5 | 38 | ||
Adenocarcinoma subtype | ||||||
Acinar | 59 | 4.6 | 50–68 | 68 | ||
Papillary | 43.5 | 7.8 | 28–59 | 37 | 4.5 | 0.009 |
Solid | 24.8 | 3 | 18.9–31 | 27 | ||
Histological gradus | ||||||
1 | 51 | 6.6 | 38–64 | 62 | 1.07 | 0.585 |
2 | 47.2 | 4.2 | 39–55 | 48 | ||
3 | 45.2 | 6.6 | 32–58 | 34 | ||
Lympho-vascular invasion | ||||||
No | 58 | 5 | 48–68 | 68 | 6.3 | 0.012 |
Yes | 38.8 | 4 | 31–47 | 37 | ||
Pathological stage | ||||||
1 | 52.4 | 4.4 | 44–61 | 62 | 2.99 | 0.224 |
2 | 44 | 6 | 33–56 | 38 | ||
3 | 38 | 5.5 | 27–49 | 37 | ||
Lymph node status | ||||||
Negative | 51 | 4 | 42–59 | 53 | 1.4 | 0.235 |
Positive | 41 | 5 | 31–51 | 37 | ||
PD-L1 | ||||||
Negative | 47.9 | 4.5 | 39–57 | 44 | 0.15 | 0.643 |
Positive | 47 | 4.7 | 38–56 | 48 | ||
IMR | ||||||
Absent | 43.5 | 4.7 | 34–53 | 37 | 2.8 | 0.246 |
Low | 46 | 5 | 36–56 | 49 | ||
Strong | 58 | 6 | 45–71 |
HR | 95% CI | p | |
---|---|---|---|
Sex | |||
Male * | 0.636 | 0.32–1.28 | 0.206 |
Female | |||
Histological type | |||
ADC * | 1.3 | 0.8–2.02 | 0.304 |
SSC | |||
ADC subtype | |||
Acinar * | 0.016 | ||
Papillary | 1.96 | 0.7–5.5 | 0.203 |
Solid | 4.2 | 1.6–11.4 | 0.004 |
Gradus | |||
1 * | 1.26 | 0.8–1.97 | 0.313 |
2 | |||
3 | |||
Lympho-vascular invasion | |||
No * | 2.15 | 1.17–3.98 | 0.015 |
Yes | |||
Pathological stage | |||
1 * | 1.33 | 0.94–1.9 | 0.108 |
2 | |||
3 | |||
Lymph node status | |||
Negative * | 1.4 | 0.79–2.5 | 0.241 |
Positive | |||
PD-L1 expression | |||
Negative * | 0.87 | 0.48–1.6 | 0.646 |
Positive | |||
IMR | |||
Absent + Low | 2 | 0.79–5 | 0.142 |
Strong * |
Lived (Months) | ||||
---|---|---|---|---|
≤24 | >24 | p * | ||
Lymph node status; n (%) | ||||
Negative | 28 (60%) | 16 (55%) | 12 (67%) | 0.635 |
Positive | 19 (40%) | 13 (45%) | 6 (33%) | |
PD-L1; n (%) | ||||
Negative | 29 (62%) | 20 (69%) | 9 (50%) | 0.321 |
Positive | 18 (38%) | 9 (31%) | 9 (50%) | |
Gradus; n (%) | ||||
1 | 6 (13%) | 2 (7%) | 4 (22%) | 0.190 |
2 | 24 (32%) | 14 (50%) | 10 (56%) | |
3 | 16 (35%) | 12 (43%) | 4 (22%) | |
Lympho-vascular invasion; n (%) | ||||
No | 16 (34%) | 9 (31%) | 7 (39%) | 0.814 |
Yes | 31 (66%) | 20 (69%) | 11 (61%) | |
Histological type; n (%) | ||||
ADC | 25 (56%) | 16 (57%) | 9 (53%) | 1 |
SCC | 20 (44%) | 12 (43%) | 8 (47%) | |
Subtype of ADC; n (%) | ||||
Acinar | 9 (37.5%) | 5 (33.3%) | 4 (44.4%) | small sample size |
Papillary | 6 (25%) | 4 (26.7%) | 2 (22.2%) | |
Solid | 9 (37.5%) | 6 (40%) | 3 (33.3%) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Simundza, I.; Krnic, D.; Juricic, J.; Benzon, B.; Simundza, R.; Stanicic, I.M.; Capkun, V.; Vukojevic, K.; Glavina Durdov, M. Expression of PD-L1 Is Associated with Inflammatory Microenvironment in Surgical Specimens of Non-Small Cell Lung Cancer. J. Pers. Med. 2021, 11, 767. https://0-doi-org.brum.beds.ac.uk/10.3390/jpm11080767
Simundza I, Krnic D, Juricic J, Benzon B, Simundza R, Stanicic IM, Capkun V, Vukojevic K, Glavina Durdov M. Expression of PD-L1 Is Associated with Inflammatory Microenvironment in Surgical Specimens of Non-Small Cell Lung Cancer. Journal of Personalized Medicine. 2021; 11(8):767. https://0-doi-org.brum.beds.ac.uk/10.3390/jpm11080767
Chicago/Turabian StyleSimundza, Ivan, Dragan Krnic, Josko Juricic, Benjamin Benzon, Rina Simundza, Ivan Mario Stanicic, Vesna Capkun, Katarina Vukojevic, and Merica Glavina Durdov. 2021. "Expression of PD-L1 Is Associated with Inflammatory Microenvironment in Surgical Specimens of Non-Small Cell Lung Cancer" Journal of Personalized Medicine 11, no. 8: 767. https://0-doi-org.brum.beds.ac.uk/10.3390/jpm11080767